← Back to Search

Pentraxin

Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis (STARSCAPE Trial)

Phase 3
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline up to 1 year
Awards & highlights

Summary

This trial is testing a lab-made protein called pentraxin-2 in people with idiopathic pulmonary fibrosis (IPF). The goal is to see if it can reduce lung inflammation and scarring. This could help improve breathing for people with this serious lung disease. PRM-151, a lab-made protein, has shown promise in reducing fibrosis in earlier studies and was well tolerated.

Eligible Conditions
  • Idiopathic Pulmonary Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline up to 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change in St. George Respiratory Questionnaire (SGRQ) Total Score
Change in University of California, San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ)
Survival

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Zinpentraxin AlfaExperimental Treatment1 Intervention
Participants will receive intravenous (IV) infusions of Zinpentraxin Alfa over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive IV infusions of placebo over 50-70 minutes on Days 1, 3 and 5, followed by infusions Q4W to Week 48.

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,444 Previous Clinical Trials
1,092,457 Total Patients Enrolled
16 Trials studying Idiopathic Pulmonary Fibrosis
3,894 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Clinical TrialsStudy DirectorHoffmann-La Roche
2,212 Previous Clinical Trials
891,751 Total Patients Enrolled
16 Trials studying Idiopathic Pulmonary Fibrosis
4,129 Patients Enrolled for Idiopathic Pulmonary Fibrosis
~148 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top